Optimal extent of dopamine d2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis

Journal of Clinical Psychopharmacology

Volumn 33, Issue 3, 2013, Pages 398-404

  Iyo, Masaomi ^a,b   Tadokoro, Shigenori ^a   Kanahara, Nobuhisa ^a   Hashimoto, Tasuku ^a   Niitsu, Tomihisa ^c   Watanabe, Hiroyuki ^a   Hashimoto, Kenji ^b  

^a CHIBA UNIVERSITY   (Japan)

^b Division of Clinical Neuroscience   (Japan)

^c CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

antipsychotics; dopamine D2 receptors; dopamine supersensitivity; late onset psychosis; occupancy; schizophrenia

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT;

ARTICLE; CONCENTRATION (PARAMETERS); DISEASE EXACERBATION; DOPAMINE SUPERSENSITIVITY PSYCHOSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LATE ONSET PSYCHOSIS; MENTAL PATIENT; MENTAL STRESS; NEUROTRANSMISSION; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UPREGULATION;

AGE OF ONSET; ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE; HUMANS; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 84877580810     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31828ea95c     Document Type: Article

References (50)

1. Saha S, Chant D, Welham J, et al. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005; 2(5): e141.
2. McIlwain ME, Harrison J, Wheeler AJ, et al. Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatr Dis Treat. 2011; 7: 135-149.
3. Snyder SH. Dopamine receptors, neuroleptics, and schizophrenia. Am J Psychiatry. 1981; 138: 460-464.
4. Seeman P, Lee T, Chau-Wong M, et al. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976; 261: 717-719.
5. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. Schizophrenia Patient Outcomes Research Team (PORT): the 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010; 36(1): 71-93.
6. Dickey B, Normand SL, Eisen S, et al. Associations between adherence to guidelines for antipsychotic dose and health status, side effects, and patient care experiences. Med Care. 2006; 44(9): 827-834.
7. Wheeler A. Explicit versus implicit review to explore combination antipsychotic prescribing. J Eval Clin Pract. 2009; 15(4): 685-691.
8. Ulrich S,Wurthmann C, Brosz M, et al. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinet. 1998; 34(3): 227-263.
9. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000; 157: 514-520.
10. Howes OD, Egerton A, Allan V, et al. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des. 2009; 15(22): 2550-2559.
11. Uchida H, Kapur S, Mulsant BH, et al. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. Am J Geriatr Psychiatry. 2009; 17(3): 255-263.
12. Galderisi S, Maj M. Deficit schizophrenia: an overview of clinical, biological and treatment aspects. Eur Psychiatry. 2009; 24: 493-500.
13. Chouinard G, Chouinard VA. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom. 2008; 77: 69-77.
14. Seeman P. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine d2(high) receptors. CNS Neurosci Ther. 2011; 17(2): 118-132.
15. Silvestri S, Seeman MV, Negrete JC, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl). 2000; 152(2): 174-180.
16. Seeman P, Bzowej NH, Guan HC, et al. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology. 1987; 1(1): 5-15.
17. Sasaki H, Hashimoto K, Maeda Y, et al. Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats. Life Sci. 1995; 56(25): PL443-7.
18. Sasaki H, Hashimoto K, Inada T, et al. Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol. Eur J Pharmacol. 1995; 282(1-3): 71-76.
19. Tadokoro S, Okamura N, Sekine Y, et al. Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr Bull. 2012; 38: 1012-1020.
20. Casey DE. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry. 2004; 65(S9): 25-28.
21. Siegfried SL, Fleischhacker W, Lieberman JA. Pharmacological treatment of schizophrenia. In: Lieberman JA and Murray RM, eds. Comprehensive Care of Schizophrenia, A Textbook of Clinical Management. London UK: Martin Dunitz Ltd; 2001: 59-94.
22. Wong DF, Wagner HN Jr, Dannals RF, et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science. 1984; 226(4681): 1393-1396.
23. Iyo M, Yamasaki T. The detection of age-related decrease of dopamine D1, D2 and serotonin 5-HT2 receptors in living human brain. Prog Neuropsychopharmacol Biol Psychiatry. 1993; 17(3): 415-421.
24. Cervenka S, Halldin C, Farde L. Age-related diurnal effect on D2 receptor binding: a preliminary PET study. Int J Neuropsychopharmacol. 2008; 11(5): 671-678.
25. Weiss S, Sebben M, Garcia-Sainz JA, et al. D2-dopamine receptor-mediated inhibition of cyclic AMP formation in striatal neurons in primary culture. Mol Pharmacol. 1985; 27(6): 595-599.
26. Enz A, Goldstein M, Meller E. Dopamine agonist-induced elevation of striatal acetylcholine: relationship between receptor occupancy and response in normal and denervated rat striatum. Mol Pharmacol. 1990; 37(4): 560-565.
27. Uchida H, Takeuchi H, Graff-Guerrero A, et al. Predicting dopamine d2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011; 31(3): 318-325.
28. List S, Seeman P. Neuroleptic/dopamine receptors: elevation and reversal. Adv Biochem Psychopharmacol. 1980; 24: 95-101.
29. Farde L, Wiesel FA, Halldin C, et al. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry. 1988; 45(1): 71-76.
30. Iyo M, Itoh T, Yamasaki T, et al. D2 receptor occupancy and plasma concentration of antipsychotics. Biol Psychiatry. 1990; 28(12): 1067-1070.
31. Chouinard G, Creese I, Boisvert D, et al. High neuroleptic plasma levels in patients manifesting supersensitivity psychosis. Biol Psychiatry. 1982; 17: 849-852.
32. Mena MA, de Yebenes JG. Drug-induced parkinsonism. Expert Opin Drug Saf. 2006; 5(6): 759-771.
33. Alexopoulos GS, Streim J, Carpenter D, et al. Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004; 65(S2): 5-99.
34. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002; 47(1): 27-38.
35. Chouinard G, Sultan S. Treatment of neuroleptic-induced supersensitivity psychosis with antiepileptic drugs: report of a series of 43 cases. Psychopharmacol Bull. 1990; 26: 337-341.
36. Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res. 1991; 5: 21-33.
37. Brunelin J, d'Amato T, Van Os J, et al. Increased left striatal dopamine transmission in unaffected siblings of schizophrenia patients in response to acute metabolic stress. Psychiatry Res. 2010; 181(2): 130-135.
38. Fallon P, Dursun SM. A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis. J Psychopharmacol. 2011; 25(6): 755-762.
39. Chouinard G, Annable L, Ross-Chouinard A, et al. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol. 1988; 8: 21SY26S.
40. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry. 1991; 48: 739-745.
41. Tenback DE, van Harten PN, Slooff CJ, et al. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. J Psychopharmacol. 2010; 24(7): 1031-1035.
42. Li CR, Chung YC, Park TW, et al. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug. World J Biol Psychiatry. 2009; 10: 919-924.
43. Huang M, Li Z, Prus AJ, et al. 5-HT2A and 5-HT2C receptor antagonism enhances risperidone-induced dopamine (DA) efflux in rat medial prefrontal cortex (mpfc) and diminishes it in the nucleus accumbens (NAC). Neurosci. 2005; Abstract 914.10.
44. Voruganti LP, Awad AG. Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects? Can J Psychiatry. 2004; 49(5): 285-289.
45. Kim JH, Son YD, Kim HK, et al. Antipsychotic-associated mental side effects and their relationship to dopamine D2 receptor occupancy in striatal subdivisions: a high-resolution PET study with [11C]raclopride. J Clin Psychopharmacol. 2011; 31(4): 507-511.
46. Voruganti L, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl). 2004; 171(2): 121-132.
47. Owen RT. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic. Drugs Today (Barc). 2007; 43(4): 249-258.
48. Eerdekens M, Van Hove I, Remmerie B, et al. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res. 2004; 70(1): 91-100.
49. Kimura H, Kanahara N, Watanabe H, et al. Potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis. Schizophr Res. 2013; 145: 130-131.
50. Di Lorenzo R, Amoretti A, Forghieri M, et al. Aripiprazole: effectiveness and safety under naturalistic conditions. Exp Clin Psychopharmacol. 2007; 15: 569-575.